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Abstract
Purpose To estimate the cost per skeletal-related event
(SRE) in patients with bone metastases secondary to solid
tumours in the Spanish healthcare setting.
Methods Patients diagnosed with bone metastases sec-
ondary to breast, prostate or lung cancer were included in
this multicentre, observational study. SREs are defined as
pathologic fracture (vertebral and non-vertebral fracture),
radiation to bone, spinal cord compression or surgery to
bone. Health resource utilisation associated with these
events (inpatient stays, outpatient, emergency room and
home health visits, nursing home stays and procedures)
were collected retrospectively for all SREs that occurred in
the 97 days prior to enrolment and prospectively during
follow-up. Unit costs were obtained from the 2010 eSalud
healthcare costs database.
Results A total of 93 Spanish patients with solid tumours
were included (31 had breast cancer, 21 prostate cancer and
41 lung cancer), contributing a total of 143 SREs to this
cost analysis. Inpatient stays (between 9.0 and 29.9 days of
mean length of stay per inpatient stay by SRE type) and
outpatient visits (between 1.7 and 6.4 mean visits per SRE
type) were the most frequently reported types of health
resources utilised. The mean cost per SRE was between
€2,377.79 (radiation to bone) and €7,902.62 (spinal cord
compression).
Conclusion SREs are associated with a significant con-
sumption of healthcare resources that generate a substantial
economic burden for the Spanish healthcare system.
Keywords Skeletal-related events  SRE  Bone
metastases  Health care resource utilisation  Costs study
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Introduction
Patients with solid tumours are highly susceptible to
developing bone metastases. The incidence of bone
metastases is 65–75 % in patients with advanced breast and
prostate cancer and 20–60 % in other solid tumours such as
in the lung, bladder, kidney or thyroid [1].
In these patients, bone metastases are a common cause
of morbidity or skeletal complications. These complica-
tions are referred to as skeletal-related events (SREs) and
include: pathologic fractures (PF) [vertebral (VF) and non-
vertebral (NVF)], radiation to bone (RB), spinal cord
compression (SCC), and surgery to bone (SB) [2–5].
The incidence of SREs has been reported in several
studies, mainly estimated through retrospective data col-
lected in the placebo arms of the bisphosphonate clinical
trials (previously considered to be the standard of care for
the prevention of SREs) [6]. During the 2 years of follow-
up, nearly 70 % of patients with breast cancer treated with
placebo had C1 skeletal complication [1]. It is also known
that patients who have previously suffered a SRE are at a
higher risk of experiencing subsequent SREs [7–10]. SREs
have a potential negative effect on the quality of life of
patients [11–14], and can be associated with serious com-
plications that can affect morbidity and mortality [15].
From a healthcare system perspective, suffering SRE is
also related to increased health resource consumption that
is directly related to increased medical costs [16].
In Spain there is an absence of studies that have ana-
lysed in-depth the health resource use associated with
SREs. Being able to estimate the associated costs from this
information is essential to perform rational allocation of
resources across the Spanish healthcare system.
Between 2008 and 2010, a multicentre study (STARS)
[17] was performed to establish health resource use asso-
ciated with SREs in patients with bone metastases sec-
ondary to breast, prostate or lung cancer or bone lesions
associated with multiple myeloma. A total of 478 patients
with solid tumours from six countries (Canada, Germany,
Italy, Spain, the United Kingdom and the United States of
America) were included; 93 patients were recruited in
Spain. Herein, we review the Spanish data set for the
patients with solid tumours and describe the cost conver-
sions used to estimate the cost by SRE type.
Methods
Primary objective and outcome measures
The primary study objective was to estimate the health
resource utilisation associated with SREs by type of SRE
and tumour type. The primary outcome measures included
number and duration of patient stays; number of outpatient
visits; number of emergency room and home health visits;
and number and type of procedures.
Study design
These analyses are based on the Spanish data collected in a
multicenter, observational study (STARS). Patients were
recruited between July 2008 and May 2010 and were fol-
lowed for up to 18–21 months. Planned enrolment was 250
patients per country, with an annual attrition (drop out and
death) assumed to be approximately 20 % for breast cancer
and multiple myeloma (data not included in this analysis),
38 % for prostate cancer, and 55 % for lung cancer.
Therefore, a country accruing 250 subjects had an expected
total follow-up of 281 patient-year (including both patients
with solid tumours and multiple myeloma).
As previously reported for the overall European cohort
of this study by Bahl et al. [17], health resource utilisation
data were collected prospectively for the duration of the
subject’s participation in the study, and retrospectively
through extraction of data from patients’ charts for all
SREs occurring in the 97-day period before recruitment.
Study population
Eligible patients were aged C18 years, diagnosed with
bone metastases secondary to cancer of the breast, prostate
or lung (per clinical practice at the participating centre),
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status 0, 1 or 2 and at least one SRE within 97 days
of providing signed informed consent. Patients were
excluded if they had participated in a clinical trial for the
treatment of bone metastases or had a life expectancy of
less than 6 months (as determined by the treating physi-
cian). The study was authorised by the Independent Ethics
Committee of each participating site and the Spanish
Agency of Medicines and Medical Devices and was per-
formed following the principles of the Declaration of
Helsinki.
Statistical analysis
All statistical analyses performed on the variables of
resources used as a consequence of developing a SRE were
descriptive. For continuous variables, the mean, median,
standard deviation (SD) and minimum and maximum val-
ues were reported. For qualitative variables, the frequency
and percentage were reported. These analyses were per-
formed and summarised for all SRE types and outcome
measures.
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Use of health resources
An electronic case report form was used to extract infor-
mation about the health resources used, as listed above.
Data were collected prospectively from patient enrolment
and retrospectively (97 days) through reviewing medical
charts and other relevant hospital and outpatient records.
Attribution of health resource use associated with a SRE
was performed by the investigators. In the event that
patients experienced more than one SRE during the study
period, the investigator determined which SRE any
resource use should be allocated to. Radiation to bone or
surgery to bone could be excluded from the health resource
utilisation analyses if they were determined to be second-
ary to a primary SRE.
Cost estimate by type of SRE
Patients with solid tumours were grouped in a single
cohort. Costs of SREs were estimated from the standpoint
of the National Health System; thus we only considered the
direct costs derived from the management of the SREs, and
the total cost was estimated per type of SRE. This cost
includes the sum of all costs of health resources used by
type of SRE collected. The unit costs of each resource
(outpatient visits, hospital stay days, procedures, etc.) were
obtained from the Spanish database of costs (eSalud) [19]
(Table 1).
The costs were estimated at 2010 Euros, as the study
reflects clinical practice between 2008 and 2010 and cost
conversion analyses were conducted during 2011 (when
cost data for 2010 were available).
Cost conversion
The costs of SREs were estimated by associating the health
resources attributed by the investigators to each type of
SRE with the respective average unit costs (Table 1)
through several formulae (one for each resource item). For
example, the cost of hospital stays (Ch) for NVF was
estimated using the equation: ChNVF ¼
P
mean number
facility staysu 9 mean duration facility staysu 9 daily
costu. Where u is the type of unit to which the patient with
NVF was admitted (i.e. general unit, intensive care unit,
etc.). These equations were validated by Oblikue Con-
sulting (administrators of the eSalud cost database [19])
and by the authors of this publication.
The cost of PF was calculated as the weighted mean of
the cost of VF and NVF, from the weight observed in the
cohort of patients with breast, prostate and lung cancer.
Results
Baseline demographics
A total of 93 patients with solid tumours were recruited
across 17 Spanish sites. Demographic characteristics are
shown in Table 2. Patients experienced a total of 143 SREs
(38 reported prospectively and 105 recorded retrospec-
tively) in the health resource utilisation cost conversion
analysis, distributed as follows: PF N = 25 (VF N = 10
and NVF N = 15), RB N = 96, SCC N = 15 and SB
N = 7. Over 60 % of the patients in each cohort had
experienced a SRE prior to retrospective collection period
before enrolment although almost half of the patients
recruited were receiving treatment with a bisphosphonate
at or prior to recruitment. Mean patient follow-up was
7.1 months (SD 5.2) for patients with breast cancer,
5.9 months (SD 4.6) for patients with prostate cancer and
3.6 months (SD 3.8) for patients with lung cancer.
Health resource utilisation
Hospitalisations
The percentage of SREs requiring hospital admission by
SRE type were as follows: 100.0 % of SB, 73.3 % of SCC,
60.0 % of VF, 40.0 % of NVF, and 16.7 % of RB. Among
those SREs requiring an inpatient stay, the longest mean
duration of inpatient stay per inpatient stay was reported to
be 29.9 days for VF, 21.6 days for SCC, 20.8 days for RB,
14.4 days for NVF and 9.0 days for SB.
Outpatient visits
RB was the SRE that required the highest percentage of
outpatient visits (74.0 %), followed by VF (70.0 %), NVF
(66.7 %), SCC (33.3 %) and SB (28.6 %). RB events also
had the highest mean number of outpatient visits (6.4 visits
per SRE). For the other SRE types, the mean number of
visits was as follows: VF 2.8 visits; NVF 1.9 visits; SB 1.7
visits; and SCC 2.5 visits.
Visits to the emergency room
Visits to the emergency room were uncommon. The SRE
requiring the most visits to the emergency room was SCC
with an average of 0.3 visits per SRE. For the other
SREs, excluding SB that did not require visits to the
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emergency room, the mean number of visits ranged from
0.0 to 0.2.
Procedures
Procedures included all tests and procedures completed
during outpatient visits. The SRE requiring the highest
number of procedures per SRE was RB with a mean of 6.4
procedures per SRE. In the outpatient setting, VF and SCC
required 2.6 and 2.5 procedures per SRE, respectively,
where as NVF and SB both required 1.7 procedures per SRE.
External beam radiation therapy was the procedure most
commonly used for the treatment of SREs, with a mean of
4.2, 1.1, 1.7 and 0.4 per RB, SCC, VF and NVF, respectively.
Table 1 Units costs used in cost conversion for Spain [18]
Type of resource Single unit cost
Hospital stay days by type of unit
General unit €252.84
Intensive care unit €1,094.50
Oncology unit €434.49
Radiation therapy unit €534.13
Rehabilitation facility €415.04
Rehabilitation unit €372.13
Surgical unit €403.51
Others €252.84
Type of resource Mean unit cost Minimum cost Maximum cost
Day hospital
General unit (daily cost) €182.43 €96.60 €290.30
Outpatient visits
Emergency physician/nurse €139.19 €49.36 €310.32
General surgery €64.44 €48.34 €80.55
Nurse €20.41 €10.24 €46.70
Oncologist €79.35 €77.75 €80.94
Physical/occupational therapy €11.06 €3.68 €20.13
Primary healthcare €43.08 €19.51 €63.90
Radiation oncologist/radiotherapist €102.10 €76.57 €127.63
Radiologist €70.65 €52.98 €88.31
Emergency room visits
Emergency room €139.19 €49.36 €310.32
Home health visits
Mean cost per visit €64.25 €27.17 €127.80
Daily nursing home stay
General unit (mean daily cost) €133.14 €66.27 €161.73
Procedures completed during the outpatient visits
Care of wounds/debridement €1,538.39 €689.93 €2,234.09
Positron emission tomography/computerised
tomography (PET-CT)
€1,148.29 €1,044.31 €1,233.14
Magnetic resonance imaging (MRI) €241.91 €161.35 €611.18
Computed tomography (CT) €169.02 €54.32 €323.87
Physical examination €106.03 €93.79 €118.27
Radionuclides €76.29 €53.57 €115.88
Laboratory tests €56.93 €25.33 €117.23
X-rays €31.66 €11.27 €67.94
External beam radiation therapy €15.17
Intensity-modulated radiation therapy (IMRT) €15.17
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Home health visits and nursing home stays
With regard to home health visits and nursing home stays,
only one case with SCC demanded this resource, with a
stay of 103 days for the nursing home.
Costs by type of SRE
Hospital stays were the main component of costs, com-
prising between 64 % of the total cost (in the case of RB)
and 94 % (in the case of VF) (Table 3). The cost by SRE
type for patients with solid tumours, estimated through cost
conversion, ranged from €2,377.79 for RB, to €7,902.62
for SCC (Table 3).
VF represented 40 % of all PF and NVF the remaining
60 %. Table 4 shows the cost of the four SRE types
described in this analysis, integrating the cost of VF and
NVF into a single cost based on the above-mentioned
weighting.
Table 2 Baseline characteristics and history of the disease by type of tumour
Breast cancer (N = 31) Prostate cancer (N = 21) Lung cancer (N = 41)
Sex, n (%)
Female 28 (90.3) 0 (0.0) 13 (31.7)
Male 3 (9.7) 21 (100.0) 28 (68.3)
Age (years)
Median (range) 56 (38–79) 68 (50–86) 59 (35–80)
Age group, n (%)
\65 years 20 (64.5) 7 (33.3) 26 (63.4)
C65 years 11 (35.5) 14 (66.7) 15 (36.6)
ECOG performance status, n (%)
0 6 (19.4) 6 (28.6) 7 (17.1)
1 12 (38.7) 10 (47.6) 17 (41.5)
2 13 (41.9) 5 (23.8) 17 (41.5)
History of SREs, n (%)a
Yes 20 (64.5) 14 (66.7) 27 (65.9)
No 11 (35.5) 7 (33.3) 14 (34.1)
Time from the diagnosis of the primary tumour to recruitment (months)
Median (range) 62.7 (0.6–259.9) 68.3 (0.6–261.2) 3.5 (0.3–49.1)
Time from the diagnosis of the bone metastasis to recruitment (months)
Median (range) 4.86 (0.2–125.1) 11.10 (0.2–107.6) 1.81 (0.0–34.2)
Duration of prospective follow-up (months)
Median (range) 6.87 (0.2–18.2) 4.63 (0.5–17.7) 2.60 (0.2–17.3)
Type of follow-up for all SREsb
Prospective, n (%) 11 (23.4) 16 (44.4) 11 (18.3)
Retrospective, n (%) 36 (76.6) 20 (55.6) 49 (81.7)
Prior bisphosphonate use, n (%) 21 (67.8) 11 (52.4) 16 (39.0)
Time from first administration to recruitment (months)
Median (Q1, Q3) 6.0 (2.5, 35.1) 5.5 (1.4, 8.6) 0.9 (0.4, 1.7)
SREs skeletal-related events, ECOG eastern cooperative oncology group
a Patients suffering any SRE in a period prior to recruitment of over 97 days
b Percentages calculated based on number of SREs
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Discussion
This is the first study reporting a cost analysis of SREs in
Spanish patients with bone metastases secondary to solid
tumours based on data from a multicenter, observational
study.
The data from this study illustrate that in addition to the
well-reported devastating clinical burden that SREs impose
on patients with metastatic bone disease, SREs are also
associated with a substantial economic burden to the
Spanish Healthcare system, as also reported in a retro-
spective database analysis conducted in Spain by Pockett
et al. [16]. The vast majority of the associated health
resource utilisation is derived from a requirement for
inpatient stays (often of substantial duration) and outpatient
visits as well as a substantial number of procedures. Of
these resources, inpatient stays generally contribute the
most to the cost of each SRE type. As might be anticipated
due to the complicated nature of their treatment, SCC and
VF were the SREs associated with the highest management
costs (7,902.62€ and 6,968.18€, respectively), driven by
the fact that the majority of them (73.3 and 60.0 %)
required lengthy hospitalisations (with an average of 21.6
and 29.9 days per inpatient stay, respectively). Although
hospitalisation was also required in all cases of SB, the
average length of stay per inpatient stay was shorter
(9.0 days) and thus the total cost of management was lower
4,262.67€ than that reported for SCC and VF. NVF had a
cost of 3,209.03€ and RB was the SRE associated with a
lowest management costs (2,377.79€), perhaps due to the
fact that it is generally managed at ambulatory level
(74.0 % of patients required 6.4 outpatient visits in aver-
age, and only 16.7 % required hospitalisation).
Our data are comparable to those reported by Pockett
et al. [16], the only retrospective review of data published
to date, which was based on the minimum basic data set of
28,162 cancer patients hospitalised during 2003 in Spain.
This study also analysed the hospital burden associated
with SREs in patients with breast, prostate or lung cancer
and bone metastases. Mean hospital stay was reported to
range from 12 to 20 days by SRE and tumour type, which
is within the range observed in our study: from 9 days for
SB to 30 days for VF per inpatient stay.
With regard to costs, Pockett et al. reported that for the
first hospital admission due to a SRE, costs were €3,757,
€3,585 and €4,298 (in Euros, of the year 2000), respec-
tively, for patients with breast, prostate and lung cancer.
These costs are in the range of those calculated in this study
(between €2,377.79 for radiation to bone and €7,902.62 for
spinal cord compression). However, it should be noted that
in this study, costs should be higher than that reported by
Pockett et al. mainly due to the fact that cost of outpatient
visits and other costs are also included. Furthermore, our
analysis has been conducted 10 years after that of Pocket
et al. (year 2010 vs. 2000).
Our results may be conservative and underestimate the
total burden of SREs. By study design, investigators
directly attributed resources to the SREs. It is possible that
not all investigators were able to access all records of
resource use at all sites (for instance information about
home health visits is not always shared between primary
care physicians and hospitals). Furthermore, only health
resources associated with SREs were investigated; pain
requiring additional health resource use and lengthy inpa-
tient stays was not considered as a SRE although evidence
suggests that more than a third of the patients with bone
metastases suffer severe pain [20] requiring hospital
admission for analgesic titration of opioids or anaesthetic
Table 3 Breakdown of costs by type of SRE and resource used
Non-vertebral fracture
(%)
Vertebral fracture
(%)
Radiation to bone
(%)
Spinal cord compression
(%)
Surgery to bone
(%)
Hospital stay €2,941.56 (92) €6,560.57 (94) €1,520.78 (64) €6,609.24 (84) €3,762.19 (88)
Outpatient visits €135.12 (4) €243.45 (3) €639.29 (27) €245.90 (3) €58.30 (1)
Emergency room
visits
€27.84 (1) €27.84 (0) €4.18 (0) €45.93 (1) €0.00 (0)
Home health visits €0.00 (0) €0.00 (0) €0.00 (0) €4.50 (0) €0.00 (0)
Nursing home stay €0.00 (0) €0.00 (0) €0.00 (0) €914.23 (12) €0.00 (0)
Procedures €104.52 (3) €136.33 (2) €213.55 (9) €82.82 (1) €442.19 (10)
Total cost by SRE €3,209.03 €6,968.18 €2,377.79 €7,902.62 €4,262.67
SRE skeletal-related event
Table 4 Mean cost of SREs by type of SRE
Type of SRE Mean cost
Pathologic fracture €4,712.69
Radiation to bone €2,377.79
Spinal cord compression €7,902.62
Surgery to bone €4,262.67
SREs skeletal-related events
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interventional techniques. Cost of treatment with bisphos-
phonates was also not included as their use was not spec-
ified in the study protocol and limited data on the dose and
frequency of their administration were recorded. It should
also be noted that direct non-healthcare costs or indirect
costs such as transportation to/from hospital visits, pay-
ment of caregivers, sick leave, etc. were also not consid-
ered in this analysis. Similarly, patients with ECOG
performance status [2 and overall survival \6 months
were not included, despite the fact that they may arguably
require more healthcare resources associated with their
more advanced disease state.
Other important limitations of this study are associated
with the difficulties to obtain information about some
healthcare resources and associate them with a unit cost.
An attempt was made to avoid double attribution of costs
considering, for instance, only procedures performed in
outpatient visits, as in the Spanish unit costs procedures
performed in hospital admissions are already included in
the price/day of stay.
One aim of this cost conversion was to calculate the
mean cost of SREs by type of tumour. A total of 31 patients
with breast cancer, 21 with prostate cancer, and 41 with
lung cancer were included in the study, experiencing a total
of 143 SREs included in the cost analysis. Due to the low
number of events when patients were separated by tumour
and SRE type, it was decided to calculate aggregated
resource use and costs by type of SRE for all solid tumours,
assuming that the resource use and costs, for instance, for
SB were the same in patients with breast, prostate or lung
cancer. This assumption was later confirmed by the results
of this study. Despite this, one potential weakness of this
analysis was the limited number of SREs included for some
SRE types, mainly SCC and SB. Nevertheless, these results
concluded that hospitalisation is the main cost driver across
all SREs, which was confirmed by the results of the overall
European analysis of the STARS study, which included a
total of 893 SREs [17].
Despite the possible limitations associated with obser-
vational studies, data from other research support the
underlying fact that all SREs are a major burden for
patients with regard to worsening health quality, need for
hospital admissions, impairment of physical and emotional
health and reduced survival [14, 21, 22]. Notably, patients
experienced multiple skeletal complications even during
the short follow-up of the study (38 prospective SREs
reported for 93 patients with mean follow-up of approxi-
mately 4–7 months, varying by tumour type), which further
illustrates the substantial burden of disease. Thus, pre-
venting SREs using the most appropriate interventions is
important to achieve a considerable reduction in patient
burden as well as potentially reducing the requirement for
costly hospitalisations and decreasing associated treatment
costs across the Spanish national health system.
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